The estimated Net Worth of Steven M Fruchtman is at least $949 Tysiąc dollars as of 13 March 2024. Dr Fruchtman owns over 23,111 units of Onconova Therapeutics Inc stock worth over $83,519 and over the last 10 years he sold ONTX stock worth over $0. In addition, he makes $865,438 as CEO i Pres & Director at Onconova Therapeutics Inc.
Dr has made over 11 trades of the Onconova Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 23,111 units of ONTX stock worth $23,111 on 13 March 2024.
The largest trade he's ever made was buying 149,000 units of Onconova Therapeutics Inc stock on 25 January 2019 worth over $29,800. On average, Dr trades about 12,660 units every 108 days since 2015. As of 13 March 2024 he still owns at least 83,519 units of Onconova Therapeutics Inc stock.
You can see the complete history of Dr Fruchtman stock trades at the bottom of the page.
Dr. Steven M. Fruchtman is the CEO, Pres & Director at Onconova Therapeutics Inc.
As the CEO i Pres & Director of Onconova Therapeutics Inc, the total compensation of Dr Fruchtman at Onconova Therapeutics Inc is $865,438. There are no executives at Onconova Therapeutics Inc getting paid more.
Dr Fruchtman is 70, he's been the CEO i Pres & Director of Onconova Therapeutics Inc since . There are 2 older and 9 younger executives at Onconova Therapeutics Inc. The oldest executive at Onconova Therapeutics Inc is Henry Bienen, 77, who is the Director.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 oraz Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: